Popular Stories

chronic pain Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Energy
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Sorrento could be the next breakout stock. Find out why!

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is in the spotlight after receiving a “Buy” rating along with a $30 price target from Ram Selvaraju an analyst at H.C Wainwright, implying a nearly 275% upside from its current levels. We take a look at reasons for the...

4 Companies Making Their Mark on the Global Nerve Stimulator Market

Nerve Stimulation is a process that involves the use of electrical stimulation technology to treat chronic pain and is categorized into Spinal Cord Stimulation and Peripheral Nerve Stimulation. These are further classified into deep brain stimulators, vagus nerve stimulators, spinal cord, sacral nerve and gastric...

Zelira Therapeutics Aims to Disrupt the Global Medical Cannabis Market

Zelira Therapeutics (OTCQB: ZLDAF), a biopharmaceutical Company developing cannabinoid-based formulations for the treatment of a wide range of medical conditions, announced full enrollment in its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment for non-cancer pain. The study intends to evaluate the...

Baudax Bio Scores a Big Win with the FDA approval of ANJESO

Baudax Bio (NASDAQ: BXRX), a pharmaceutical Company developing novel therapeutics for Acute Care Settings, announed the approval of a New Drug Application ( NDA) for ANJESO (meloxicam injection), intended for alleviating moderate to severe pain, either as a standalone treatment or in combination with other...

Collegium Pharmaceutical Carving a Niche in the Pain Management Industry

Collegium Pharmaceutical (NASDAQ: COLL), a Speciality Pharmaceutical Company focussed on developing novel abuse-deterrent therapeutics for pain relief and management, announced the closing of its acquisition of the Nucynta franchise from Assertio Therapeutics (NASDAQ: ASRT), in consideration for $375.0 million in cash at closing, less royalties...

Can Nektar Therapeutics Bounce Back from its Massive Tumble?

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...

WordPress Video Lightbox Plugin